• Determine therapeutic response of oral capecitabine in recurrent high grade gliomas by establishing the radiographic response rate using modified Macdonald criteria. [ Time Frame: 2.5 Years ] [ Designated as safety issue: No ]
  

• Evaluate the longitudinal effect of oral capecitabine on traditional quality of life and performance status measurements. [ Time Frame: 2.5 Years ] [ Designated as safety issue: No ]
  
• Evaluate the longitudinal tolerability of capecitabine using standardized toxicity criteria. [ Time Frame: 2.5 Years ] [ Designated as safety issue: Yes ]
  

Drug: Capecitabine
1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.

High grade gliomas (HGGs) represent a heterogenous group of primary brain tumors that share WHO grade III or IV classification (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed glioma, and glioblastoma multiforme). Despite the upfront use of surgery, radiation, and chemotherapy, high grade gliomas uniformly result in recurrence and death. Palliative chemotherapy offers an improvement in time to progression, symptom control, quality of life, and potential survival; however, no established chemotherapy regimen for recurrence exists and new treatments are needed. Oral capecitabine is a rationale strategy for therapeutic palliation of recurrent high grade gliomas given its oral administration, its well-known kinetics and toxicities, its non-competitive toxicities to other high grade glioma treatments, its well established management algorithms, its established evidence of entry into the central nervous system, and its evidence of safety and efficacy in malignancies in the central nervous system.